Drugs / MAGE-3.A1 peptide
last change Apr 2008 re-read 2 minutes ago

MAGE-3.A1 peptide

Peptide

Developed for
melanoma
Investigated by
Ludwig Institute for Cancer Research

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00145145 Jan → Apr 2005 melanoma Ludwig Institute for Cancer Research Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MAGE-3.A1 peptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00145145
Modality Peptide “MAGE-3.A1 peptide (300 µg)” NCT00145145